Expression of estrogen receptor beta isoforms in pancreatic adenocarcinoma.

Mamoun Younes,Kanchan Singh,Jennifer M. Bailey,Charles J. Ly,Pamela S. Younes,Atilla Ertan

doi:10.18632/oncotarget.26503

Mamoun Younes, Kanchan Singh + Show 4 more

Open Access

https://doi.org/10.18632/oncotarget.26503

Copy DOI

Abstract

Limited studies have shown that some patients with pancreatic adenocarcinoma (PAC) may benefit from treatment with tamoxifen. PAC has been shown to be largely negative for estrogen receptor alpha (ER-alpha). The aim of this pilot study was to investigate ER-beta expression in human PAC. Sections of tissue microarray with 18 evaluable cases of human PAC were stained by immunohistochemistry (IHC) for ER-beta1, ER-beta2, ER-beta5, and Cyclin A. The levels of ER-beta isoform expression and the S-phase fraction (SPF) were determined using quantitative digital image analysis.Higher mean and median ER-beta2 levels correlated with male sex (p = 0.057 and p = 0.035, respectively), older age (p = 0.005 and p = 0.006, respectively), and lower pT stage (p = 0.008 and p = 0.009). Mean and median ER-beta5 levels correlated negatively with SPF (p = 0.021 and p = 0.047, respectively). Mean ER-beta1 expression did not correlate with any of the above mentioned clinicopathologic factors. The findings in this pilot study, although should be considered preliminary, suggest that some ER-beta isoforms may play a role in the biology of PAC. Additional larger studies are needed to confirm our findings, and to determine whether ER-beta may be considered for future targeted therapy.

Highlights

It has been estimated that 53,670 individuals will be diagnosed with pancreatic adenocarcinoma (PAC) and 43,090 will die of it in the United States in 2017 [1]
All three estrogen receptor (ER)-β isoforms were expressed in PAC (Figure 1), the levels of expression of each isoform varied between tumors (Figure 2)
Because of the small sample size studied from each tumor, heterogeneity of ER-β expression within each individual adenocarcinoma cannot be determined from this study

Summary

Introduction

It has been estimated that 53,670 individuals will be diagnosed with pancreatic adenocarcinoma (PAC) and 43,090 will die of it in the United States in 2017 [1]. In vitro studies showed that PAC cell lines express estrogen receptor beta The aim of this pilot study was to investigate ER-β protein expression in human PAC using immunohistochemistry (IHC)

Methods

Results

Conclusion